Syngene Q3 FY26: Revenue down 3%, PAT falls 44% on margin pressure
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.4 pts less than Nifty Smallcap 250 and 6.5 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syngene Q3 FY26 revenue fell 3% YoY to Rs. 917 Cr; 9M revenue up 3% to Rs. 2,702 Cr. EBITDA dropped 26% to Rs. 225 Cr with margin compressing to 24% from 31%. PAT (before exceptional) fell 44% to Rs. 73 Cr. An exceptional charge of Rs. 58 Cr (net of tax) tied to new Labour Code gratuity impact cut PAT after exceptional to Rs. 15 Cr. Management cited ongoing weakness from a single large-molecule client; Bristol Myers Squibb partnership extended to 2035.
Weak quarter with margin compression and one-off Labour Code charge. BMS extension to 2035 is a long-term positive. Watch for single-client drag to ease.